It has always been Straumann’s matter of principle that products undergo a rigorous research process starting in the laboratories before they are launched. The last step on this way to marketability is clinical research. Roxolid® went through a intensive scientific program with two clinical studies at launch documenting the product with a 1-year follow-up.
- Presentation with 1 year follow up (FU) of pilot study
- Presentation with 1 year follow up (FU) of Multi Center study
The entire clinical program for Roxolid® includes over 400 patients which were treated with more than 500 Roxolid® implants.
| Content | Center(s) | Indication | Patient population | Status |
|---|---|---|---|---|
| Pilot study of implant new material | 2 centers in UK | Part. Edentulous | 22 patients | 1 yr FU presented |
| Multi Center Study comparing Roxolid vs. Ti | 8 centers in Europe | Full edentulous | 91 patients | 1 yr FU presented |
| Roxolid in the daily practice (NIS) | over 50 centers in EU and USA |
Various | Over 250 patients | Recruitment closed |
| Show reduced need of augmentation and measure quality of life of patients with hypodontia |
University of Cork | Hypodontia | 20 patients | Recruitment |
| Comparison Roxolid 3.3 mm vs. Ti 4.1 mm | Zurich/Harvard | Part. Edentulous | 40 patients | Recruitment |
| Performance of Roxolid implants for single tooth replacement in narrow spaces |
University of Berne | Single tooth | 40 patients | Recruitment |
